ArticleACR open rheumatology2026
Scavenging of Isolevuglandins Attenuates Neutrophil Migration and Neutrophil Extracellular Trap Formation in Systemic Lupus Erythematosus.
Article in ACR open rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveSystemic lupus erythematosus (SLE) is an autoimmune disease that affects numerous organs. Neutrophil extracellular traps (NETs) contribute to sterile inflammation and autoantibody generation in SLE. Isolevuglandins (isoLGs) are reactive oxygen species that are formed during NETosis and contribute to chromatin expansion. Scavenging of isoLGs attenuates SLE disease activity and hypertension in murine models of SLE. We hypothesized that isoLGs drive NETosis in SLE.
methodsNeutrophils were isolated from patients with SLE (n = 6), treated with the isoLG scavenger ethyl-2-hydroxybenzylamine (Et-2-HOBA), and evaluated for NETosis by immunofluorescence. Single-cell sequencing was performed on lymphoid tissue from SLE-prone B6.SLE123 mice treated with the isoLG scavenger 2-hydroxybenzylamine (2-HOBA). Flow cytometry was performed to quantify neutrophils and NETs in B6.SLE123 mice (n = 11-15).
resultsIn neutrophils isolated from patients with SLE, Et-2-HOBA prevented NETosis (P < 0.05). In SLE-prone mice, 2-HOBA reduced neutrophil counts, inflammatory gene expression, circulating neutrophil counts (P < 0.0001), and aortic NETosis (P < 0.05).
conclusionThese findings suggest that isoLGs contribute to systemic autoimmunity and vascular inflammation by driving neutrophil migration and NETosis in SLE.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.